文献速递浆细胞疾病

源自TP53 CRISPR/Cas9人骨髓瘤细胞系的p53评分可预测生存并揭示BAX在BH3模拟物反应中的主要作用

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
PubMed 文献 · Blood · 2024-01-01

研究利用CRISPR/Cas9从TP53+/+及TP53-/mut t(4;14)人骨髓瘤细胞系构建TP53-/-克隆,建立含13个基因的功能性p53评分,可区分TP53状态并预测骨髓瘤患者总生存;p53调控的BAX影响MCL1 BH3模拟物S63845敏感性,MCL1与BCL2 BH3模拟物联用对97%患者样本有效。

要点

  • 功能性p53评分含13个p53沉默后特异性下调基因,可区分细胞系及患者样本TP53状态。
  • 该评分可识别双等位TP53失活骨髓瘤患者,并在coMMpass和CASSIOPEA队列中预测总生存。
  • p53调控的BAX表达与S63845敏感性相关,MCL1与BCL2 BH3模拟物联用显示协同效力。

核心结论

  • 建立了可识别双等位TP53失活骨髓瘤细胞的功能性p53评分。
  • p53调控的BAX对骨髓瘤细胞对BH3模拟物的最佳反应至关重要。
  • MCL1与BCL2 BH3模拟物联用可能对双等位TP53失活患者更有效,该人群仍存在未满足的医疗需求。

研究设计与样本

  • 利用CRISPR/Cas9技术从TP53+/+和TP53-/mut t(4;14)人骨髓瘤细胞系(HMCLs)构建TP53-/-克隆。
  • 从TP53+/+ HMCLs来源的TP53-/-克隆共有的17个失调基因中,建立涉及13个p53沉默后特异性下调基因的功能性p53评分。
  • 在Multiple Myeloma Research Foundation-coMMpass和CASSIOPEA队列中评估评分的预测价值。
  • 采用单细胞RNA测序分析联用BH3模拟物后存活骨髓瘤细胞的p53评分。

主要发现

  • 功能性p53评分可将克隆、骨髓瘤细胞系及其他癌细胞系按TP53状态区分。
  • 该评分能有效识别双等位TP53失活骨髓瘤患者样本,并预测总生存。
  • 13个基因中p53调控的BAX表达与MCL1 BH3模拟物S63845敏感性相关,并通过减少MCL1-BAX复合物直接影响敏感性。
  • 对S63845的耐药可被MCL1与BCL2 BH3模拟物联用克服,二者显示协同效力。
  • BH3模拟物联用对97%的患者样本有效,无论是否伴del17p;单细胞RNA测序显示联用后存活骨髓瘤细胞p53评分较低,提示p53评分较高的骨髓瘤细胞对BH3模拟物更敏感。

关键数值与推荐

  • 功能性p53评分涉及13个基因,这些基因在p53沉默后特异性下调。
  • BH3模拟物联用对97%的患者样本有效,包括伴或不伴del17p的样本。

临床怎么用

  • 作者认为MCL1与BCL2 BH3模拟物联用可能对双等位TP53失活骨髓瘤患者更有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To establish a strict p53-dependent gene-expression profile, TP53-/- clones were derived from TP53+/+ and TP53-/mut t(4;14) human myeloma cell lines (HMCLs) using CRISPR/Cas9 technology. From the 17 dysregulated genes shared between the TP53-/- clones from TP53+/+ HMCLs, we established a functional p53 score, involving 13 genes specifically downregulated upon p53 silencing. This functional score segregated clones and myeloma cell lines as well as other cancer cell lines according to their TP53 status. The score efficiently identified samples from patients with myeloma with biallelic TP53 inactivation and was predictive of overall survival in Multiple Myeloma Research Foundation-coMMpass and CASSIOPEA cohorts. At the functional level, we showed that among the 13 genes, p53-regulated BAX expression correlated with and directly affected the MCL1 BH3 mimetic S63845 sensitivity of myeloma cells by decreasing MCL1-BAX complexes. However, resistance to S63845 was overcome by combining MCL1 and BCL2 BH3 mimetics, which displayed synergistic efficacy. The combination of BH3 mimetics was effective in 97% of patient samples with or without del17p. Nevertheless, single-cell RNA sequencing analysis showed that myeloma cells surviving the combination had lower p53 score, showing that myeloma cells with higher p53 score were more sensitive to BH3 mimetics. Taken together, we established a functional p53 score that identifies myeloma cells with biallelic TP53 invalidation, demonstrated that p53-regulated BAX is critical for optimal cell response to BH3 mimetics, and showed that MCL1 and BCL2 BH3 mimetics in combination may be of greater effectiveness for patients with biallelic TP53 invalidation, for whom there is still an unmet medical need.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Durand R, Descamps G, Bellanger C, et al. A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics. Blood. 2024. PMID: 38096363. doi:10.1182/blood.2023021581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。